


S21		S22	
S23		S24	

9. A preparation method for the compound of claim 1, comprising the following step:



In an inert solvent, reacting formula A compound with formula B compound to obtain formula I compound;

5 wherein Q is a leaving group; ring A, X, R₁ and R₂ are defined as in claim 1.

10. A pharmaceutical composition, comprising: therapeutically effective amount of the compound of any of claims 1-8, or a pharmaceutically acceptable salt, hydrate or solvate thereof, and optionally a pharmaceutically acceptable carrier or excipient.

11. Use of the compound I of claim 1, or a pharmaceutically acceptable salt, hydrate or solvate thereof in the preparation of medicament for the prevention and / or treatment of FGFR-related diseases.

12. The use of claim 11, wherein the tumor-related disease is selected from the group consisting of breast cancer, lung cancer, bladder cancer, gastric cancer, pancreatic cancer, prostate cancer, colon cancer, myeloma, liver cancer, Melanoma, head and neck cancer, thyroid cancer, renal cell carcinoma, glioblastoma and testicular cancer.

13. A protein tyrosine kinase enzyme activity inhibitor comprising an inhibitory effective amount of the compound according to any of claims 1-4, or a pharmaceutically acceptable salt, hydrate or solvent thereof.

14. A pharmaceutical composition for treating cancer or diseases associated with protein tyrosine kinase activity, wherein the pharmaceutical composition comprises a therapeutically effective amount of a compound according to any of claims 1-8, or a pharmaceutically acceptable salt, hydrate or solvent thereof as an active ingredient.